ALPS Advisors
TVTX icon

ALPS Advisors’s Travere Therapeutics TVTX Stock Holding History

ALPS Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$7.35M Buy
124,893
+30,912
+33% +$1.89M 0.03% 213
2026
Q2 		$5.34M Buy
93,981
+18,885
+25% +$837K 0.03% 264
2026
Q1 		$2.23M Buy
75,096
+1,833
+3% +$54.8K 0.01% 382
2025
Q4 		$2.8M Buy
73,263
+26,020
+55% +$846K 0.02% 338
2025
Q3 		$1.13M Sell
47,243
-705
-1% -$13.3K 0.01% 489
2025
Q2 		$710K Buy
+47,948
New +$795K ﹤0.01% 581
2024
Q2 		– Sell
-53,672
Closed -$414K – 1003
2024
Q1 		$414K Buy
53,672
+6,617
+14% +$55.8K ﹤0.01% 618
2023
Q4 		$423K Sell
47,055
-8,319
-15% -$60.6K ﹤0.01% 637
2023
Q3 		$495K Buy
55,374
+531
+1% +$7.49K ﹤0.01% 599
2023
Q2 		$842K Buy
54,843
+6,731
+14% +$122K 0.01% 525
2023
Q1 		$1.08M Buy
48,112
+4,612
+11% +$98K 0.01% 455
2022
Q4 		$915K Buy
43,500
+8,587
+25% +$182K 0.01% 501
2022
Q3 		$860K Sell
34,913
-2,766
-7% -$71.5K 0.01% 496
2022
Q2 		$913K Sell
37,679
-27,576
-42% -$694K 0.01% 496
2022
Q1 		$1.68M Sell
65,255
-5,599
-8% -$149K 0.02% 258
2021
Q4 		$2.2M Sell
70,854
-3,557
-5% -$100K 0.02% 281
2021
Q3 		$1.8M Sell
74,411
-5,214
-7% -$95.8K 0.02% 331
2021
Q2 		$1.16M Sell
79,625
-29,350
-27% -$579K 0.01% 388
2021
Q1 		$2.72M Buy
108,975
+16,963
+18% +$469K 0.03% 228
2020
Q4 		$2.51M Buy
+92,012
New +$2.15M 0.03% 243

Other funds holding TVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Stephens Investment Management Group
Stephens Investment Management Group Houston, Texas $9.29B AUM 41.16% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Emerald Mutual Fund Advisers Trust
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

ALPS Advisors's TVTX Position: Q3 2026 in Review

ALPS Advisors increased its Travere Therapeutics (TVTX) stake by 33% in Q3 2026, buying an estimated $1.89M and bringing the position to 124,893 shares worth $7.35M. The position accounts for 0.03% of the portfolio, ranked #213.

ALPS Advisors first reported a position in TVTX in Q4 2020 and has held it in 20 quarters since. 158 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

  • ALPS Advisors held 124,893 shares of Travere Therapeutics worth $7.35M as of Q3 2026.
  • ALPS Advisors bought 30,912 Travere Therapeutics shares in Q3 2026, an estimated $1.89M.
  • Travere Therapeutics made up 0.03% of ALPS Advisors's portfolio in Q3 2026, its #213 holding.
  • ALPS Advisors first reported a position in Travere Therapeutics in Q4 2020 and has held it in 20 quarters since.
  • 158 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on ALPS Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.